This is the final post in a three-part series on artificial intelligence in healthcare.
Of all of the marketplace dynamics and advances currently posing a threat to pharma’s traditional methods and models, artificial intelligence and advanced data science are causing their fair share of consternation. I recently addressed this issue with my colleague John Piccone, a ZS principal and advanced data science expert who previously led IBM Watson Health’s life sciences offerings, and he succinctly stated the commercial transformation challenge that lies ahead: “Pharma’s role is going to change from educating people to educating algorithms.” How can pharma get there? What steps can companies start taking now to adapt? John has some ideas.